These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37716223)

  • 1. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
    Marsh LA; Kim TH; Zhang M; Kubalanza K; Treece CL; Chase D; Memarzadeh S; Salani R; Karlan B; Rao J; Konecny GE
    Gynecol Oncol; 2023 Oct; 177():173-179. PubMed ID: 37716223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
    Ramspott JP; Baert T; MacKintosh ML; Traut A; Ataseven B; Bommert M; Heitz F; Plett H; Schneider S; Waltering KU; Heikaus S; Harter P; du Bois A
    Arch Gynecol Obstet; 2021 Oct; 304(4):1021-1032. PubMed ID: 33661392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
    Liontos M; Andrikopoulou A; Koutsoukos K; Markellos C; Skafida E; Fiste O; Kaparelou M; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
    J Ovarian Res; 2021 Nov; 14(1):148. PubMed ID: 34724958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
    Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Liontos M; Sotiropoulou M; Kaparelou M; Tzannis K; Tsironis G; Kyriazoglou A; Tsiara A; Zakopoulou R; Koutsoukos K; Zagouri F; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Bamias A
    Gynecol Oncol; 2020 Jun; 157(3):599-605. PubMed ID: 32173048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
    Barrington DA; Felix AS; Owda R; Suarez AA; Cohen DW; Senter L; Copeland LJ; Fowler JM; Backes FJ; Cohn DE; Bixel KL; O'Malley DM; Salani R; Cosgrove CM
    Surg Oncol; 2020 Sep; 34():40-45. PubMed ID: 32891351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.
    Jani I; Lastra RR; Brito KS; Liao C; Lazo I; Lee NK; Yamada SD; Kurnit KC
    Int J Gynecol Cancer; 2021 Jun; 31(6):852-858. PubMed ID: 33833085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study.
    Wu MF; Liang JX; Li H; Ye YF; Liang WF; Wang LJ; Zhang BZ; Chen Q; Lin ZQ; Li J
    BJOG; 2022 Nov; 129 Suppl 2():5-13. PubMed ID: 36485072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
    Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
    Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease.
    Liang WF; Wang LJ; Li H; Liu CH; Wu MF; Li J
    J Cancer; 2021; 12(3):946-953. PubMed ID: 33403051
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
    Michaan N; Chong WY; Han NY; Lim MC; Park SY
    Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Nitecki R; Fleming ND; Fellman BM; Meyer LA; Sood AK; Lu KH; Rauh-Hain JA
    Gynecol Oncol; 2021 Jun; 161(3):660-667. PubMed ID: 33867146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with
    Lee YJ; Shin YK; Kim NR; Kim SI; Lee YY; Park JY; Kim JW; Cho HW; Lee JY
    J Gynecol Oncol; 2024 Nov; 35(6):e73. PubMed ID: 38551024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram.
    Liang WF; Li H; Wu JY; Liu CH; Wu MF; Li J
    Front Oncol; 2020; 10():560888. PubMed ID: 33123471
    [No Abstract]   [Full Text] [Related]  

  • 18. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Persenaire C; Pyrzak A; Barber EL
    J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.